• About us
• Contact

Advertisement

Organisation › Details

Sandoz (division of Novartis)

Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people's lives. We contribute to society's ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1,000 molecules, covering all major therapeutic areas, accounted for 2017 sales of USD 10.1 billion. In 2017, our products reached well over 500 million patients. Sandoz is headquartered in Holzkirchen, in Germany's Greater Munich area. *

 

	Start	2003-05-01 renamed
	Group	Novartis (Group)
	Industry	DRUGS, GENERICS
	Industry 2	DRUGS, BIOGEN, GENERICS (biosimilars / biogenerics)
	Person	Saynor, Richard (Novartis 2019Q1– CEO of Sandoz)
	Region	Holzkirchen
	Country	Germany
	Street	25 Industriestr.
	City	83607 Holzkirchen
	Tel	+49-8024-476-0
		Address record changed: 2024-01-05
Basic data	Employees	n. a.
	Currency	USD
	Annual sales	9,600,000,000 (sales (annual) 2021-12-31)
		* Document for »About Section«: Novartis AG. (7/27/18). "Press Release: Sandoz Receives European Commission Approval for Biosimilar Hyrimoz (adalimumab)". Holzkirchen.
		Record changed: 2024-01-20

Advertisement

More documents for Novartis (Group)

• [1] FundaMental Pharma GmbH. (4/11/24). "Press Release: FundaMental Pharma Appoints Dr. Dirk Beher as Chief Executive Officer". Heidelberg....
• [2] BioNTech SE. (3/20/24). "Press Release: BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer". Mainz....
• [3] Scinai Immunotherapeutics Ltd.. (2/13/24). "Press Release: Scinai Welcomes Liat Halpert as Head of Business Development and Sales". Jerusalem....
• [4] MorphoSys AG. (2/5/24). "Press Release: MorphoSys Enters into Business Combination Agreement to Be Acquired by Novartis for € 2.7 Billion Equity Value. Tafasitamab Sold to Incyte". Planegg....
• [5] Calypso Biotech B.V.. (1/8/24). "Press Release: Calypso Enters into Agreement to Be Acquired by Novartis". Amsterdam....
• [6] Shanghai Argo Biopharmaceutical Co., Ltd.. (1/7/24). "Press Release: Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis". Shanghai....
• [7] SanReno Therapeutics. (1/5/24). "Press Release: SanReno Therapeutics Announces Acquisition by Novartis in Pivotal Transaction to Bring Forward Transformative Therapeutics in Kidney Disease". Shanghai....
• [8] Legend Biotech Corporation. (11/13/23). "Press Release: Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3". Somerset, NJ....
• [9] Sandoz Group AG. (10/4/23). "Press Release: Sandoz Enters New Era as Standalone Global Leader and European Champion in Generic and Biosimilar Medicines". Basel....
• [10] BeiGene, Ltd.. (9/19/23). "Press Release: BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody Tevimbra (tislelizumab)". Basel & Beijing & Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.